Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD26m

    Last close

    AUD0.00

    ▲ 0.00 (50.00%)

    Cereno Scientific

    MCap

    SEK1,751m

    Last close

    SEK6.23

    ▲ 1.02 (19.58%)

    Vection Technologies

    MCap

    AUD11m

    Last close

    AUD0.01

    ▲ 0.00 (14.29%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Argent Biopharma (LSE: RGT)

Last close As at 10/10/2024

GBP0.27

— 0.00 (0.00%)

Market capitalisation

GBP14m

Argent Biopharma is an Australia-headquartered specialist medical cannabis biopharma company, which has most of its operations based in Europe.

Latest Insights

View More

Healthcare | QuickView

Argent Biopharma — An innovative approach to drug development

Healthcare | Update

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

Healthcare | Update

MGC Pharmaceuticals — Initial CannEpil purchase orders received

Healthcare | Update

MGC Pharmaceuticals — MGC Derma sale completed
Visit Website

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Igor Bluvstein

    CFO

  • Roby Zomer

    Managing Director and Co-CEO

  • Yifat Steuer

    COO

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 63.1 51.4 (64.7)
Relative 63.3 49.6 (68.3)
52 week high/low 80.0p/10.5p

Financials

Argent BioPharma is a clinical-stage specialty biopharma company developing therapeutics targeting areas of unmet need. Currently focused on CNS conditions and immunology, Argent has a broad pipeline of assets, led by CannEpil (drug-resistant epilepsy), CimetrA (acute lung disease) and CogniCann (CNS disorders). The first two are available under special access schemes in markets such as the UK, US and EU, generating early revenue streams as well as real-world evidence, which should aid regulatory outcomes. Argent has a strong internal IP position with two EU-GMP R&D and manufacturing sites (in Malta and Slovenia) supporting in-house drug development. These could potentially be monetised via contract manufacturing services. We expect the most significant upcoming catalysts to be the investigational new drug (IND) filings with the FDA for CannEpil and CimetrA, expected by end 2025 according to management.

Y/E Jun Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2008A 0.1 (1.2) (1.4) (11.5) N/A N/A
2009A 0.1 (0.4) (0.7) (2.4) N/A N/A
2010E N/A N/A N/A N/A N/A N/A
2011E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

MGC Pharmaceuticals — Rapid prescription growth in Australia and the UK

Update

Healthcare

MGC Pharmaceuticals — Initial CannEpil purchase orders received

Healthcare

QuickView

Argent Biopharma — An innovative approach to drug development

Update

Healthcare

MGC Pharmaceuticals — MGC Derma sale completed

Initiation

Healthcare

MGC Pharmaceuticals — Cannabis-based medicines and cosmetics

Thematics

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free